Results 41 to 50 of about 93,898 (384)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study

Journal of Clinical Medicine, 2023
Introduction: The co-presence of bronchiectasis (BE) in severe eosinophilic asthma (SEA) is common. Data about the effectiveness of benralizumab in patients with SEA and BE (SEA + BE) are lacking.
R. Campisi, S. Nolasco, C. Pelaia, P. Impellizzeri, M. D’Amato, Andrea Portacci, L. Ricciardi, G. Scioscia, N. Crimi, N. Scichilone, M. F. Foschino Barbaro, G. Pelaia, G. E. Carpagnano, A. Vatrella, C. Crimi   +14 more
semanticscholar   +1 more source

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]

, 2017
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny, Golam, Sarowar, Hillyer, Elizabeth V, Kerkhof, Marjan, Price, David B, Soriano, Joan B, Tran, Trung N   +6 more
core   +1 more source

Antagonism of cytokine-induced eosinophil accumulation in asthma [PDF]

, 2012
Peer reviewedPublisher ...
Walsh, Garry M.
core   +2 more sources

Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction – PROMISE

ERJ Open Research, 2023
Background Randomised controlled trials have shown that benralizumab, an anti-interleukin-5 receptor monoclonal antibody, reduces exacerbations and oral corticosteroid dose and improves asthma control and lung function in severe eosinophilic asthma.
F. Schleich, C. Moermans, Laurence Seidel, C. Kempeneers, G. Louis, F. Rogister, S. Tombu, L. Pottier, A. Poirrier, S. Ziant, M. Henket, C. Sanchez, V. Paulus, F. Guissard, A. Donneau, R. Louis   +15 more
semanticscholar   +1 more source

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils [PDF]

, 2017
INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma.
Brusselle, Guy, Germinaro, Matthew, Weiss, Sivan, Zangrilli, James   +3 more
core   +2 more sources

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma

BMJ Open Respiratory Research, 2023
Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD)
R. Chan, B. Lipworth
semanticscholar   +1 more source

Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma

Allergology International, 2017
Type-2/eosinophilic inflammation plays a pivotal role in asthma. The identification of severe type-2/eosinophilic asthma is important for improving the management of patients with asthma.
Tadao Nagasaki, Hisako Matsumoto, Kenji Izuhara, Yoshihiro Kanemitsu, Yuji Tohda, Takahiko Horiguchi, Hideo Kita, Keisuke Tomii, Masaki Fujimura, Akihito Yokoyama, Yasutaka Nakano, Soichiro Hozawa, Isao Ito, Tsuyoshi Oguma, Yumi Izuhara, Tomoko Tajiri, Toshiyuki Iwata, Tetsuji Yokoyama, Akio Niimi, Michiaki Mishima   +19 more
doaj   +1 more source

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,, BEGHE', Bianca, Fabbri, Lm3, Papi, A1   +3 more
core   +1 more source

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis

ERJ Open Research, 2023
Background The current definition of severe eosinophilic asthma (SEA) super-responders to biologic treatment does not include patients with other eosinophil-based comorbidities.
Andrea Portacci, R. Campisi, E. Buonamico, S. Nolasco, C. Pelaia, N. Crimi, A. Benfante, Massimo Triggiani, G. Spadaro, M. Caiaffa, G. Scioscia, Aikaterini Detoraki, G. Valenti, F. Papia, Alessandra Tomasello, N. Scichilone, G. Pelaia, C. Crimi, G. E. Carpagnano   +18 more
semanticscholar   +1 more source

Prevalence of asthma and COPD and blood eosinophil count in a middle-aged Belgian population [PDF]

, 2019
Various phenotypes exist in asthma and Chronic Obstructive Pulmonary Disease (COPD). These are important to identify in order to guide treatment decisions.
Brusselle, Guy, De Buyzere, Marc, Lahousse, Lies, Rietzschel, Ernst, Wijnant, Sara   +4 more
core   +1 more source